Annuncio • Aug 27
Exeltis USA, Inc. completed the acquisition of Agile Therapeutics, Inc. (OTCPK:AGRX) from Beryl Capital Management LLC and others. Exeltis USA, Inc. entered into a letter of intent to acquire Agile Therapeutics, Inc. (OTCPK:AGRX) from Beryl Capital Management LLC and others for $10.7 million on April 16, 2024. Exeltis USA, Inc. entered into a definitive merger agreement to acquire Agile Therapeutics, Inc. (OTCPK:AGRX) from Beryl Capital Management LLC and others for $10.7 million on June 25, 2024. Exeltis will acquire Agile for $1.52 per share in cash. In case of termination under certain circumstances, Agile would be required to pay Insud (parent of Exeltis) a termination fee of $1.26 million. Upon completion of the transaction, Agile will no longer be listed on any public market. Transaction is subject to approval by Agile’s stockholders. The Board of Directors of Agile has unanimously approved the transaction. The board of Insud Pharma, S.L. also approved the transaction. The transaction is expected to close in the third quarter of 2024.
H.C. Wainwright & Co., LLC acted as financial advisor for Agile Therapeutics, Inc. Steven M. Cohen of Morgan, Lewis & Bockius LLP acted as legal advisor for Agile Therapeutics, Inc. Mitchell S. Nussbaum of Loeb & Loeb LLP and Xavier Ruiz of RC Law LLP acted as legal advisors to Insud Pharma, S.L. and Exeltis USA, Inc. H.C. Wainwright & Co., LLC acted as fairness opinion provider to Agile Therapeutics. Broadridge Financial Solutions, Inc. acted as transfer agent to Agile Therapeutics. The engagement letter between Agile and Wainwright provides for an advisory fee in an amount equal to $1.35 million to be paid to Wainwright at the closing of the Transactions. The engagement letter also provides for the payment to Wainwright of a fee in an amount equal to $0.35 million payable on the date on which the opinion was delivered that is not conditioned upon the results of Wainwright’s evaluation and analysis or upon the conclusions reached in the opinion. Alliance Advisors LLC acted as information agent to Agile Therapeutics, Inc.
Exeltis USA, Inc. completed the acquisition of Agile Therapeutics, Inc. (OTCPK:AGRX) from Beryl Capital Management LLC and others on August 26, 2024. As of August 22, 2024, Agile Therapeutics shareholders approved the transaction. Loeb & Loeb LLP and RC Law LLP acted as legal advisors to Insud Pharma, S.L. and Exeltis USA, Inc. Annuncio • Jun 28
Agile Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $15 million. Agile Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $15 million.
Security Name: Common Stock
Security Type: Common Stock
Security Name: Series E-1 Warrants
Security Type: Equity Warrant
Security Name: Series E-2 Warrants
Security Type: Equity Warrant
Security Name: Series F Pre-funded Warrants
Security Type: Equity Warrant Annuncio • Mar 27
Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from NASDAQ Composite Index Agile Therapeutics, Inc. will be removed from NASDAQ Composite Index. Annuncio • Mar 26
Nasdaq to Suspend Common Stock of Agile Therapeutics Effective March 26 On March 22, 2024, Agile Therapeutics, Inc. (the Company") received notice from The Nasdaq Stock Market LLC that the Nasdaq Hearings Panel has determined to delist the Company's common stock. Suspension of trading inthe Company's common stock will be effective at the open of trading on March 26, 2024. Following the delisting of its common stock from the Nasdaq Capital Market, the Company will continue to be a reporting company underthe Securities Exchange Act of 1934. The Company expects its common stock will commence trading on the OTC Markets Group platform at the open of trading on March 26, 2024 under the symbol AGRX." The Company has applied for trading on the OTC-QB market. The Company has a period of 15 days from the date of the notice letter to submit a written request for a review of the Nasdaq Hearings Panel's delisting determination by the Nasdaq Listing and Hearing Review Council (the Listing Council"). The Company does not plan to appeal the Nasdaq Hearings Panel's determination and expects that a Form 25-NSE will be filed with the Securities and Exchange Commission (SEC"), which would remove the Company's common stock from listing and registration on Nasdaq. As previously disclosed, on March 27, 2023, the Company received a letter from the Nasdaq Listing Qualifications Department (the Staff") indicating that it was not in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market set in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder's equity of at least $2,500,000 (the Rule"). On June 2, 2023, based on the Staff's review of the materials submitted by the Company, the Staff granted the Company's request for an extension until September 25, 2023 to comply with the Rule. On September 27, 2023, the Company received a notice from the Staff advising the Company that the Staff had determined that the Company did not meet the terms of the extension and that unless the Company requested an appeal, the Staff would proceed with delisting. The Company submitted a hearing request to the Panel, which stayed the delisting, and the hearing was held on November 30, 2023. The Company was granted an additional period, or until March 25, 2024, to regain compliance with the Rule. Annuncio • Mar 22
Agile Therapeutics, Inc. to Report Q4, 2023 Results on Mar 28, 2024 Agile Therapeutics, Inc. announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Mar 28, 2024 Annuncio • Feb 16
Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year Ended December 31, 2023 Agile Therapeutics, Inc. provided revenue guidance for the Full Year ended December 31, 2023. For the year, the company expects net revenue to be in the range of $20 million to $21 million compared to $10.9 million for the full year 2022, representing an increase of 84% to 93%. Annuncio • Dec 12
Agile Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15 million. Agile Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.
Security Name: Common Stock
Security Type: Common Stock
Security Name: Series E-1 Warrants
Security Type: Equity Warrant
Security Name: Series E-2 Warrants
Security Type: Equity Warrant
Security Name: Series F Pre-funded Warrants
Security Type: Equity Warrant Annuncio • Oct 27
Agile Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Agile Therapeutics, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 09, 2023 Annuncio • Oct 05
Agile Therapeutics Announces Update on Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market As previously disclosed on March 27, 2023, Agile Therapeutics, Inc. (the ‘Company’) received a letter from the Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market (‘Nasdaq’) indicating that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder’s equity of at least $2,500,000 (the ‘Rule’). On June 2, 2023, based on the Staff’s review of the materials submitted by the Company, the Staff granted the Company’s request for an extension until September 25, 2023 to comply with the Rule. On September 27, 2023, the Company received a notice from the Staff advising the Company that the Staff had determined that the Company did not meet the terms of the extension and that unless the Company requests an appeal, the Staff would proceed with delisting. The Company intends to submit a hearing request to the Nasdaq Hearings Panel (the ‘Panel’), which request will stay any delisting action by the Staff at least until the hearing process concludes and any extension granted by the Panel expires. At the Panel hearing, the Company intends to present a plan to regain compliance with the Rule. In the interim, the Company’s common stock will continue to trade on the Nasdaq Capital Market at least pending the ultimate conclusion of the hearing process. Additionally, the Panel may review the Company’s plan and grant an additional 180 days from the date of the notice, until March 25, 2024, for the Company to regain compliance with the Rule. There can be no assurance that the Company’s plan will be accepted by the Panel or that, if it is, the Company will be able to regain compliance with the applicable Nasdaq listing requirements. If the Company’s common stock is delisted, it could be more difficult to buy or sell the Company’s common stock or to obtain accurate quotations, and the price of the Company’s common stock could suffer a material decline. Delisting could also impair the Company’s ability to raise capital. If trading in the Company’s common stock is suspended on the Nasdaq Capital Market or the Company’s common stock is delisted by Nasdaq, it could negatively impact the Company as it would likely reduce the liquidity and market price of the Company’s common stock, reduce the number of investors willing to hold or acquire the Company’s common stock, negatively impact the Company’s ability to access equity markets and obtain financing, and impair the Company’s ability to provide equity incentives. Annuncio • Jul 28
Agile Therapeutics, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Agile Therapeutics, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 09, 2023 Annuncio • Jul 01
Agile Therapeutics, Inc. Provides Revenue Guidance for the Year 2023 Agile Therapeutics, Inc. provides revenue guidance for the year 2023. For the year, the company expects $25-30 million in revenue largely due to Twirla. Annuncio • Jun 15
Agile Therapeutics, Inc. (NasdaqCM:AGRX) announced an agreement to acquire vitaCare Prescription Services, Inc. from GoodRx Holdings, Inc. (NasdaqGS:GDRX). Agile Therapeutics, Inc. (NasdaqCM:AGRX) announced an agreement to acquire vitaCare Prescription Services, Inc. from GoodRx Holdings, Inc. (NasdaqGS:GDRX) on June 13, 2023. Annuncio • Jun 06
Agile Therapeutics Receives an Additional 180-Day Period, or Until September 25, 2023 from Nasdaq, to Regain Compliance with Nasdaq Listing Rule 5550(b)(1) On June 2, 2023, Agile Therapeutics, Inc. (the Company") received a letter (the Extension Notice") from the Listing Qualifications Department (the Staff") of The Nasdaq Stock Market (Nasdaq") notifying the Company thatit had been granted an additional 180-day period, or until September 25, 2023, to regain compliance with Nasdaq Listing Rule 5550(b)(1). As previously disclosed on March 27, 2023, the Company received a letter from theStaff indicating that it was not in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the NasdaqCapital Market to maintain stockholders' equity of at least $2,500,000 (the Stockholders' Equity Requirement"). The Company's Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2022, reportedstockholders' equity of $(5,545,000), which is below the Stockholders' Equity Requirement for continued listing on the Nasdaq Capital Market. The Company submitted a plan to regain compliance with the Stockholders' Equity Requirement under Nasdaq Listing Rule 5550(b)(1) on May 11, 2023. Pursuant to the Extension Notice, the Company must demonstrate compliance with Nasdaq Listing Rule 5550(b)(1) on or before September 25, 2023, by furnishing to the Securities and Exchange Commission (the SEC") and Nasdaq certain information and representations on a Current Report on Form 8-K, among other obligations. If, after submitting this information to the SEC and Nasdaq as described in the Extension Notice, the Company fails to evidence compliance with Nasdaq Listing Rule 5550(b)(1) upon filing its Form 10-Q for the quarter ended September 30, 2023, the Company may be subject to delisting from Nasdaq. In the event the Company fails to regain compliance, Nasdaq will issue the Company a delisting notice, at which time the Company would have the right to a hearing before an independent panel. The hearing request would halt any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing. The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. If trading in the Company's common stock is suspended on Nasdaq or the Company's common stock is delisted by Nasdaq for any reason, it could negatively impact the Company as it would likely reduce the liquidity and market price of the Company's common stock; reduce the number of investors willing to hold or acquire the Company's common stock; negatively impact the Company's ability to access equity markets and obtain financing; and impair the Company's ability to provide equity incentives. Annuncio • May 26
Agile Therapeutics, Inc. has completed a Follow-on Equity Offering. Agile Therapeutics, Inc. has completed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,896,286
Price\Range: $3.9551
Discount Per Security: $0.2769
Security Name: Series C-1 Warrants
Security Type: Equity Warrant
Securities Offered: 1,896,286
Security Name: Series C-2 Warrants
Security Type: Equity Warrant
Securities Offered: 1,896,286 Annuncio • May 09
Agile Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023 Agile Therapeutics, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 11, 2023 Annuncio • Jan 10
Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023 Agile Therapeutics, Inc. provided revenue guidance for the full year 2023. For the period, the company expects net revenue to be in the range of $25 million - $30 million. Is New 90 Day High Low • Feb 09
New 90-day high: US$3.12 The company is up 7.0% from its price of US$2.91 on 10 November 2020. The American market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 8.0% over the same period. 